TCGA-CQ-6222-01A-11R-1915-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.600
- OXIDATIVE_PHOSPHORYLATION+0.570
- ADIPOGENESIS+0.490
- ALLOGRAFT_REJECTION+0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- COMPLEMENT+0.360
- FATTY_ACID_METABOLISM+0.360
- BILE_ACID_METABOLISM+0.340
- IL6_JAK_STAT3_SIGNALING+0.340
- INFLAMMATORY_RESPONSE+0.310
Top 10 suppressed
- E2F_TARGETS-0.670
- G2M_CHECKPOINT-0.600
- MYC_TARGETS_V1-0.460
- MYC_TARGETS_V2-0.460
- TGF_BETA_SIGNALING-0.420
- WNT_BETA_CATENIN_SIGNALING-0.420
- MITOTIC_SPINDLE-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.360
- DNA_REPAIR-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_EHVYJAVA | pilocytic astrocytoma | — | 0.860 |
| 2 | ERR2598280 | fetal | fetal | 0.851 |
| 3 | ERR2598329 | fetal | fetal | 0.847 |
| 4 | ERR2598330 | fetal | fetal | 0.841 |
| 5 | TCGA-BA-A6DB-01A-11R-A30B-07 | — | — | 0.837 |
| 6 | ERR2598281 | fetal | fetal | 0.834 |
| 7 | ERR2598267 | fetal | fetal | 0.833 |
| 8 | BS_ARBQDTT5 | pilocytic astrocytoma | — | 0.829 |
| 9 | BS_2R9TCR03 | low-grade glioma | — | 0.825 |
| 10 | ERR2598328 | fetal | fetal | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.600 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.570 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.490 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.360 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.300 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.230 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |